[EN] SUBSITUTED HYDROXYETHYLAMINE COMPOUNDS FOR TRATING ALZHEIMER'S DISEASE [FR] COMPOSES D'HYDROXYETHYLAMINE SUBSTITUES POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
Second generation of BACE-1 inhibitors part 2: Optimisation of the non-prime side substituent
摘要:
Our first generation of hydroxyethylamine transition-state mimetic BACE-1 inhibitors allowed us to validate BACE-1 as a key target for Alzheimer's disease by demonstrating amyloid lowering in an animal model, albeit at rather high doses. Finding a molecule from this series which was active at lower oral doses proved elusive and demonstrated the need to find a novel series of inhibitors with improved pharmacokinetics. This Letter describes the discovery of such inhibitors.